Viatris (VTRS) Stock Price, News & Analysis

Company Overview

Viatris Inc. (NASDAQ: VTRS) is a global diversified healthcare company formed in November 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. Headquartered in North Wales, Pennsylvania, Viatris operates across the entire pharmaceutical value chain, from research and development to manufacturing, commercialization and supply chain management. The company’s mission centers on providing access to high-quality medicines in both developed and emerging markets, addressing the needs of patients across a wide range of therapeutic areas.

The company’s core business pillars include branded medicines, generic and biosimilar products, over-the-counter consumer health solutions, and novel regulatory services. Viatris leverages a broad pipeline of off-patent and on-patent products, focusing on specialties such as cardiology, oncology support, immunology, central nervous system disorders and infectious diseases. Its biosimilar portfolio features treatments designed to increase affordability and access to biologic therapies for patients with autoimmune conditions and cancer.

Viatris maintains a global manufacturing network with facilities in North America, Europe, Asia and Latin America, ensuring supply chain resilience and regulatory compliance. In addition to traditional pharmaceutical products, the company offers digital health and adherence solutions to support patients and healthcare providers, aiming to improve treatment outcomes through integrated care pathways and technology-enabled services.

Supported by a leadership team led by President and Chief Executive Officer Michael Goettler, Viatris employs approximately 45,000 people in more than 165 countries and territories. The company’s strategic priorities include expanding access to medicines, optimizing its diversified product portfolio and driving sustainable growth through disciplined capital allocation and operational excellence.

Key Stats

• Today's Range: $9.04 to $9.15
• 50-Day Range: $8.29 to $9.34
• 52-Week Range: $6.85 to $13.55
• Volume: 6.05 million shs
• Average Volume: 10.97 million shs
• Market Capitalization: $10.73 billion
• P/E Ratio: N/A
• Dividend Yield: 5.25%
• Price Target: $10.40
• Consensus Rating: Reduce

Viatris Stock Analysis - MarketRank™

Viatris scored higher than 58% of companies evaluated by MarketBeat, and ranked 469th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Viatris has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 1 buy rating, 2 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Viatris has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -4.10%

Earnings Growth

Earnings for Viatris are expected to decrease by -4.10% in the coming year, from $2.68 to $2.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viatris is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viatris is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viatris has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.51% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Viatris has recently decreased by 63.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Viatris is a leading dividend payer. It pays a dividend yield of 5.26%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Viatris does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Viatris will have a dividend payout ratio of 18.68% next year. This indicates that Viatris will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.51% of the float of Viatris has been sold short.

Short Interest Ratio / Days to Cover

Viatris has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Viatris has recently decreased by 63.35%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.79

News Sentiment

Viatris has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Viatris this week, compared to 10 articles on an average week.

Search Interest

14 people have searched for VTRS on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

5 people have added Viatris to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Viatris insiders have bought more of their company's stock than they have sold. Specifically, they have bought $536,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.13% of the stock of Viatris is held by insiders.

Percentage Held by Institutions

79.88% of the stock of Viatris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTRS Stock Analysis - Frequently Asked Questions

How have VTRS shares performed this year?

Viatris' stock was trading at $12.45 at the start of the year. Since then, VTRS shares have decreased by 26.6% and is now trading at $9.14.

How were Viatris' earnings last quarter?

Viatris Inc. (NASDAQ:VTRS) announced its quarterly earnings data on Thursday, May, 8th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. The company's quarterly revenue was down 10.9% on a year-over-year basis.
Read the conference call transcript.

Is Viatris doing a stock buyback?

Viatris' board initiated a stock buyback program on Wednesday, February 28th 2024, which authorizes the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 6.7% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its stock is undervalued.

Who are Viatris' major shareholders?

Top institutional shareholders of Viatris include Assenagon Asset Management S.A. (0.34%), Wedge Capital Management L L P NC (0.29%), Bell Bank (0.05%) and Wealth Enhancement Advisory Services LLC (0.03%). Insiders that own company stock include Rajiv Malik, Scott Andrew Smith, Anthony Mauro, Paul Campbell, Harry Korman, Brian Roman, Xiangyang (Sean) Ni, Dillon Joellen Lyons, Andrew Cuneo and Der Meer Mohr Pauline Van.
View institutional ownership trends.

How do I buy shares of Viatris?

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viatris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viatris investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Tesla (TSLA) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 5/08/2025
• Record date for 6/16 Dividend: 5/23/2025
• Ex-Dividend for 6/16 Dividend: 5/23/2025
• Dividend Payable: 6/16/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTRS
• CIK: 1792044
• Web: www.viatris.com
• Phone: (724) 514-1800
• Fax: 724-514-1870
• Employees: 32,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Viatris: $10.40
• High Price Target: $13.00
• Low Price Target: $9.00
• Potential Upside/Downside: +13.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 3.41
• P/E Growth: N/A
• Net Income: -$634.20 million
• Net Margins: -26.45%
• Pretax Margin: -27.39%
• Return on Equity: 16.20%
• Return on Assets: 7.01%

Debt

• Debt-to-Equity Ratio: 1.02
• Current Ratio: 1.68
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $14.74 billion
• Price / Sales: 0.73
• Cash Flow: $5.11 per share
• Price / Cash Flow: 1.79
• Book Value: $15.61 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 1,173,680,000
• Free Float: 1,172,156,000
• Market Cap: $10.73 billion
• Optionable: Optionable
• Beta: 0.89